Post by
Joemare on Feb 15, 2023 7:56am
More bad news to come on Feb 28. Unfortunately.
'Business update' plugged in a quater/annual review is never a good thing for biotech.
So, three years and no partners in NASH, likely crappy preclinical work no one believes in, failed proof of concept, halt of a phase I. So, we paid, say 10-12 M$ to executives to execute a reorg of a sales-force??
Please, please, please prove me wrong on the 28.
Comment by
Trogarzon on Feb 15, 2023 8:02am
Sell the company for 3$ or take a writoff...